Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.
Clin Gastroenterol Hepatol. 2024 May;22(5):1098-1107.e3. doi: 10.1016/j.cgh.2023.11.009. Epub 2023 Nov 22.
BACKGROUND & AIMS: Acute enteric infections are well known to result in long-term gastrointestinal (GI) disorders. Although COVID-19 is principally a respiratory illness, it demonstrates significant GI tropism, possibly predisposing to prolonged gut manifestations. We aimed to examine the long-term GI impact of hospitalization with COVID-19.
Nested within a large-scale observational cohort study of patients hospitalized with COVID-19 across North America, we performed a follow-up survey of 530 survivors 12-18 months later to assess for persistent GI symptoms and their severity, and for the development of disorders of gut-brain interaction (DGBIs). Eligible patients were identified at the study site level and surveyed electronically. The survey instrument included the Rome IV Diagnostic Questionnaire for DGBI, a rating scale of 24 COVID-related symptoms, the Gastrointestinal Symptoms Rating Scale, and the Impact of Events-Revised trauma symptom questionnaire (a measure of posttraumatic stress associated with the illness experience). A regression analysis was performed to explore the factors associated with GI symptom severity at follow-up.
Of the 530 invited patients, 116 responded (52.6% females; mean age, 55.2 years), and 73 of those (60.3%) met criteria for 1 or more Rome IV DGBI at follow-up, higher than the prevalence in the US general population (P < .0001). Among patients who experienced COVID-related GI symptoms during the index hospitalization (abdominal pain, nausea, vomiting, or diarrhea), 42.1% retained at least 1 of these symptoms at follow-up; in comparison, 89.8% of respondents retained any (GI or non-GI) COVID-related symptom. The number of moderate or severe GI symptoms experienced during the initial COVID-19 illness by self-report correlated with the development of DGBI and severity of GI symptoms at follow-up. Posttraumatic stress disorder (Impact of Events-Revised score ≥33) related to the COVID-19 illness experience was identified in 41.4% of respondents and those individuals had higher DGBI prevalence and GI symptom severity. Regression analysis revealed that higher psychological trauma score (Impact of Events-Revised) was the strongest predictor of GI symptom severity at follow-up.
In this follow-up survey of patients 12-18 months after hospitalization with COVID-19, there was a high prevalence of DGBIs and persistent GI symptoms. Prolonged GI manifestations were associated with the severity of GI symptoms during hospitalization and with the degree of psychological trauma related to the illness experience.
急性肠道感染众所周知会导致长期的胃肠道(GI)疾病。尽管 COVID-19 主要是一种呼吸道疾病,但它表现出明显的肠道趋向性,可能导致肠道表现持续存在。我们旨在研究 COVID-19 住院患者的长期胃肠道影响。
在一项针对北美 COVID-19 住院患者的大规模观察队列研究中,我们对 530 名幸存者进行了 12-18 个月后的随访调查,以评估持续性胃肠道症状及其严重程度,以及肠-脑相互作用障碍(DGBI)的发展情况。在研究地点层面确定符合条件的患者,并进行电子调查。调查工具包括 DGBI 的罗马 IV 诊断问卷、24 项 COVID 相关症状评分量表、胃肠道症状评分量表和修订后的事件影响量表(用于测量与疾病经历相关的创伤后应激)。进行回归分析以探讨与随访时胃肠道症状严重程度相关的因素。
在邀请的 530 名患者中,有 116 名(52.6%为女性;平均年龄为 55.2 岁)做出了回应,其中 73 名(60.3%)在随访时符合 1 项或多项罗马 IV DGBI 标准,高于美国普通人群的患病率(<0.0001)。在经历 COVID-19 住院期间胃肠道症状(腹痛、恶心、呕吐或腹泻)的患者中,42.1%在随访时仍至少保留 1 种这些症状;相比之下,89.8%的受访者保留了任何(胃肠道或非胃肠道)COVID-19 相关症状。自我报告的初始 COVID-19 疾病期间出现的中度或重度胃肠道症状数量与 DGBI 的发展以及随访时胃肠道症状的严重程度相关。与 COVID-19 疾病经历相关的创伤后应激障碍(修订后的事件影响量表评分≥33)在 41.4%的受访者中被发现,这些个体的 DGBI 患病率和胃肠道症状严重程度更高。回归分析显示,较高的心理创伤评分(修订后的事件影响量表)是随访时胃肠道症状严重程度的最强预测因素。
在 COVID-19 住院后 12-18 个月的这项随访调查中,DGBI 和持续性胃肠道症状的患病率很高。延长的胃肠道表现与住院期间胃肠道症状的严重程度以及与疾病经历相关的心理创伤程度相关。